Streetbeat News

Regulatory

KRON

Kronos Bio presented preclinical data at ACR Convergence 2024, showing that p300 KAT inhibitors can reduce inflammation by modulating pro-inflammatory signaling pathways. The data was demonstrated in both ex vivo and in vivo models.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

PYNKF

Perimeter Medical Imaging AI reported its Q3 2024 financial results, highlighting positive market traction with its FDA-cleared product, Perimeter S-Series OCT.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

INO

INOVIO reported its Q3 2024 financial results and highlighted recent business developments, including promising immunology data for INO-3107. The data showed INO-3107's ability to induce a cytotoxic T cell response against HPV-6 and HPV-11, potentially reducing surgeries for RRP patients. Regulatory submissions for INO-3107 are on track, with a BLA submission targeted for mid-2025.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

CRNX

Crinetics Pharmaceuticals is set to present its advancements in neuroendocrine tumor treatments at the NANETS Annual Meeting. The company will debut its novel nonpeptide drug conjugate platform, highlighting the preclinical profile of its lead candidate CRN09682, which targets SST2-expressing tumors and is expected to submit an IND by early 2025.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

MSFT

The FTC is investigating Microsoft's cloud unit for potential antitrust violations, focusing on claims of market share abuse. This investigation is part of the FTC's efforts under Chair Lina Khan.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

DARE

Daré Bioscience reported its Q3 2024 financial results and provided updates on its development programs. Key highlights include progress in the Ovaprene® contraceptive study, Sildenafil Cream for female sexual arousal disorder, and other products in various stages of clinical trials. The company has received significant funding to support these initiatives.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

TSLA

Tesla's stock has entered a correction phase, experiencing significant losses due to potential policy changes from the incoming Trump administration, despite a strong post-election rally.

Portfolio Pulse from

November 14, 2024 | 9:00 pm

NDAQ

SMCI

Super Micro Computer (Nasdaq: SMCI) faces a critical deadline amid an accounting scandal, raising concerns about potential delisting from Nasdaq. Investors are worried about the stock's future.

Portfolio Pulse from

November 14, 2024 | 9:00 pm

V

Visa has disclosed that the European Commission is conducting a preliminary investigation into the fees it charges retailers. This was revealed in Visa's annual report.

Portfolio Pulse from

November 14, 2024 | 8:30 pm